Credit Suisse Upgrades BioMarin Pharmaceutical (BMRN) to Overweight
More News related to BMRN
- BioMarin to Present at the NASDAQ OMX 23rd Investor Program
- BioMarin (BMRN) Responds to News of Contamination at Genzyme (GENZ) Plant; Says Aldurazyme, Naglazyme Won't Be Impacted
- Particles Detected in Vials from Genzyme's Plant Not Expected to Impact Aldurazyme or Naglazyme
- United States Patent Office Issues Patent Covering the Approved Administration of Kuvan With Food
- BioMarin to Present at the Credit Suisse Healthcare Conference
More News related to Upgrades
- Analysts Bullish on Analog Devices (ADI) Following Q4 Results: AmTech, GC Research Upgrade, Citi Lifts Price Target
- Veeco (VECO) Shares Rally Amid Avian Upgrade
- Raymond James Upgrades AMICAS (AMCS) to Strong Buy
- RBC Upgrades Diamond Rock (DRH) to Outperform, Downgrades Hospitality Properties (HPT) to Sector Perform
- First Global Upgrades NetApp (NTAP) to Outperform; Signs of Business Stabilization & Improvement
Credit Suisse upgrades BioMarin Pharmaceutical (Nasdaq: BMRN) from Neutral to Overweight. Price target increased from $19 to $25.
To see more analyst ratings on BMRN Click Here.
BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions.
Related Categories
UpgradesStocks Mentioned
-0.30Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
